Regarding the commencement of the investment business at the subsidiary Gemseki

Our company, a consolidated subsidiary corporation,Gemseki(below"Gemseki") as unlimited liability partner (General Partner) as11has established a fund worth billions of yen, so we would like to inform you.

As part of our translational research business, we have been supporting and investing in life science startups, including biotech companies listed in Japan and the US for about20years.4We have been supporting and investing in life science startups, including biotech companies.

Additionally, our group founded and spun offWAVE Life Sciences Ltd.、Satsuma Pharmaceutical Inc.of2companies that have been listed on the US Nasdaq market, showcasing our unique achievements.

Meanwhile, as a consolidated subsidiary2017year10Launched in the monthGemsekiWe have steadily built a track record as a business development platform in the life sciences industry,2020year9In the lunar phase250undertaking over a hundred projects and promoting global licensing, partnering,M&Aand other activities.

Under such circumstances, in order to promote the platform strategy in the life science drug discovery field asSNBL ,GemsekiWe will establish a fund within our group with unlimited liability partners to further promote incubation support for biotech companies.

Our group has been advancing a paradigm shift towards translational research, including drug discovery in-house, in addition to preclinical and clinical trial contracts.

With the establishment of this fund,Gemsekiwe will be able to provide investment and incubation functions in addition to business development services to promising biotech companies we interact with daily, enabling us to offer a comprehensive drug development platform that supports the entire drug discovery process.

"Fund Overview"

 End